Bernstein Named Vertex as the Best Investment Choice in the Biotechnology Sector

Investment company Bernstein has named Vertex Pharmaceuticals as the best investment choice in the biotechnology sector. This decision was prompted by the clinical trial failure of competitor Sionna, which, according to analysts, has further strengthened Vertex's position.

Sionna announced that its drug SION-719, which was to be used alongside Vertex's Trikafta in patients with cystic fibrosis, failed to achieve its primary endpoint in phase 2 clinical trials. Following this, the company decided to halt development of the drug.

According to Bernstein analyst Jeffrey Walch, this decision has allowed Vertex to avert one of its main competitive threats. In his view, Vertex's advantage in the cystic fibrosis treatment market faces no threat at this stage. Competition is further complicated by Alyftrek, which has replaced Trikafta as the company's next-generation drug.

According to Bernstein's forecast, Vertex has sufficient time and resources to develop next-generation drugs and maintain its leadership position in the cystic fibrosis treatment market.

Source: Investing.com